key: cord-0739090-z5nktzzz
authors: Bukhari, Abrar E.
title: New-Onset of Vitiligo in a Child Following COVID-19 Vaccination
date: 2022-02-23
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2022.02.021
sha: 7fe3e805a81552d5a0cffbe8bd4198510d928b69
doc_id: 739090
cord_uid: z5nktzzz

nan

Introduction 27

Since January 2020, the ongoing COVID-19 pandemic has been a global health emergency. Vaccination is 28 a critical measure for containing the spread of COVID-19. At the end of 2020, several vaccines became 29 available. Multiple adverse events (AEs) have been reported with all the available COVID-19 vaccines. 30

This report describes a case of vitiligo in a child that started 2 weeks after she received a COVID-19 31 mRNA vaccine. 32 33 Case Report 34 Three weeks after receiving her first dose of the BNT162b2 COVID-19 m-RNA vaccine (Pfizer/BioNTech), 35 a 13-year-old healthy girl presented to an outpatient dermatology clinic complaining of light-colored 36 skin patches spreading across her body that started two weeks after vaccination. The patient had no 37 known dermatological diseases or medical conditions, no known allergies, and was not taking any 38 medications. She had not used any treatment. Her father and one paternal uncle had vitiligo that had 39 begun in adulthood; however, the patient had never had vitiligo previously. Physical examination 40 revealed a Fitzpatrick skin type 4 with multiple widespread well-defined depigmented patches 41 throughout her extremities and trunk, involving approximately 5% of her body surface area (Fig. 1a,b) . 42

Wood's lamp examination illustrated milky white accentuation of patches, which is consistent clinically 43 with vitiligo vulgaris. She was treated with a topical calcineurin inhibitor and topical steroid, and 44 

New-onset vitiligo following mRNA-1273 (Moderna) COVID-19 vaccination

Sudden onset of vitiligo after COVID-19 vaccine

A new-onset vitiligo following the inactivated COVID-19 vaccine

Counting antigen-specific CD8 T cells: a reevaluation of 118